Elite Pharmaceuticals Inc (ELTP)

[John_Langston]

Stamford, Conn. – November 20, 2014 – Purdue Pharma L.P. announced that the U.S. Food and Drug Administration (FDA) approved Hysingla ER (hydrocodone bitartrate) extended-release tablets CII, a once-daily, single-entity medication formulated using Purdue’s proprietary extended-release solid oral platform, RESISTEC™. It is the first and only hydrocodone product to be recognized by the FDA as having abuse-deterrent properties that are expected to deter misuse and abuse via chewing, snorting and injection. However, abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible.

What proof is there that Elites ART/ADT can't be abused intravenous, intranasal, or orally?